Table 3.
Odds ratio comparing proportion of alemtuzumab-treated patients with sNfL levels at or below healthy control median or 80th percentile thresholds versus SC IFNB-1a–treated patients.
| Population | Month | Odds ratio a (95% CI) | p-Value |
|---|---|---|---|
| Overall CARE-MS I | |||
| Healthy control median | 12 | 1.81 (1.20–2.74) | 0.0046 |
| 24 | 2.85 (1.84–4.43) | <0.0001 | |
| Healthy control 80th percentile | 12 | 1.68 (1.06–2.67) | 0.0270 |
| 24 | 3.01 (1.76–5.17) | <0.0001 | |
| HAD CARE-MS I | |||
| Healthy control median | 12 | 1.63 (0.79–3.36) | 0.19 |
| 24 | 6.08 (2.55–14.50) | <0.0001 | |
| Healthy control 80th percentile | 12 | 2.42 (1.11–5.26) | 0.0263 |
| 24 | 4.57 (1.71–12.23) | 0.0024 | |
CI: confidence interval; HAD: highly active disease; SC IFNB-1a: subcutaneous interferon beta-1a; sNfL: serum neurofilament light chain.
a
Odds ratio of sNfL level less than or equal to that of healthy control median or healthy control 80th percentile, adjusted for age and baseline sNfL.